erlotinib hydrochloride has been researched along with Salivary Gland Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Kaye, FJ; Lu, J; Ni, W; Wu, L; Yang, R; Yu, M; Zhou, X | 1 |
| Azuma, T; Fujishiro, Y; Matsuzaka, K; Ochiai, H; Tonogi, M; Yamane, GY | 1 |
2 other study(ies) available for erlotinib hydrochloride and Salivary Gland Neoplasms
| Article | Year |
|---|---|
Targeting Notch and EGFR signaling in human mucoepidermoid carcinoma.
Topics: Animals; Carcinoma, Mucoepidermoid; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Heterografts; Humans; Mice; Molecular Targeted Therapy; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Receptors, Notch; Salivary Gland Neoplasms; Signal Transduction; Trans-Activators; Transcription Factors; Translocation, Genetic | 2021 |
The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salivary Gland Neoplasms; Side-Population Cells | 2012 |